Format

Send to

Choose Destination
Ophthalmologica. 2017;237(3):128-138. doi: 10.1159/000458160. Epub 2017 Mar 10.

Improved Visual Outcome and Low Recurrence with Early Treatment with Intravitreal Anti-Vascular Endothelial Growth Factor in Myopic Choroidal Neovascularization.

Author information

1
Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

Abstract

PURPOSE:

The aim of this study was to determine the correlation between the duration of myopic choroidal neovascularization (CNV) and treatment outcome after anti-vascular endothelial growth factor (VEGF) injections.

METHODS:

We performed a retrospective review of treatment-naïve myopic CNV patients who were treated with anti-VEGF and followed for at least 24 months to identify factors predicting final outcome and recurrence.

RESULTS:

Among 106 eyes, a shorter duration of CNV was a significant predictor of a better final best-corrected visual acuity, even after controlling for other factors (p = 0.042). When divided into 3 groups according to CNV duration before treatment (<2, 2-8, and 8-24 weeks), the recurrence rate (19, 25, and 52%, respectively; p = 0.006) and number of injections (3.5, 4.0, and 5.5, respectively; p = 0.021) were significantly lower in eyes with a shorter duration of CNV.

CONCLUSIONS:

Early anti-VEGF treatment of myopic CNV decreased the recurrence rate and number of injections and improved visual outcome.

PMID:
28278507
DOI:
10.1159/000458160
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center